# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024
Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 pri...
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confide...
Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Perform to Outperform and announces ...
HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 ...